188 related articles for article (PubMed ID: 19339964)
1. Comparison of dose-finding designs for narrow-therapeutic-index drugs: concentration-controlled vs. dose-controlled trials.
Lledó-García R; Hennig S; Karlsson MO
Clin Pharmacol Ther; 2009 Jul; 86(1):62-9. PubMed ID: 19339964
[TBL] [Abstract][Full Text] [Related]
2. The influence of underlying assumptions on evaluating the relative merits of concentration-controlled and dose-controlled trials.
Lledó-García R; Hennig S; Karlsson MO
Clin Pharmacol Ther; 2009 Jul; 86(1):70-6. PubMed ID: 19279565
[TBL] [Abstract][Full Text] [Related]
3. Ethically attractive dose-finding designs for drugs with a narrow therapeutic index.
Lledó-García R; Hennig S; Nyberg J; Hooker AC; Karlsson MO
J Clin Pharmacol; 2012 Jan; 52(1):29-38. PubMed ID: 21228403
[TBL] [Abstract][Full Text] [Related]
4. Randomized concentration-controlled trials: motivations, use, and limitations.
Kraiczi H; Jang T; Ludden T; Peck CC
Clin Pharmacol Ther; 2003 Sep; 74(3):203-14. PubMed ID: 12966364
[No Abstract] [Full Text] [Related]
5. Optimal designs for estimating the most successful dose.
Zohar S; O'Quigley J
Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
[TBL] [Abstract][Full Text] [Related]
6. Interpretation and inference in noninferiority randomized controlled trials in drug research.
Wangge G; Klungel OH; Roes KC; de Boer A; Hoes AW; Knol MJ
Clin Pharmacol Ther; 2010 Sep; 88(3):420-3. PubMed ID: 20668448
[TBL] [Abstract][Full Text] [Related]
7. Designs for dose-escalation trials with quantitative responses.
Bailey RA
Stat Med; 2009 Dec; 28(30):3721-38. PubMed ID: 19579226
[TBL] [Abstract][Full Text] [Related]
8. Improved up-and-down designs for phase I trials.
Ivanova A; Montazer-Haghighi A; Mohanty SG; Durham SD
Stat Med; 2003 Jan; 22(1):69-82. PubMed ID: 12486752
[TBL] [Abstract][Full Text] [Related]
9. Optimal adaptive design in clinical drug development: a simulation example.
Maloney A; Karlsson MO; Simonsson US
J Clin Pharmacol; 2007 Oct; 47(10):1231-43. PubMed ID: 17906158
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II trials with a prospective control.
Jung SH
Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
[TBL] [Abstract][Full Text] [Related]
11. Commentary on 'Designs for dose-escalation trials with quantitative responses'.
Rosenberger WF; Manukyan Z
Stat Med; 2009 Dec; 28(30):3751-3; discussion 3759-60. PubMed ID: 19967756
[No Abstract] [Full Text] [Related]
12. Commentary on 'Designs for dose-escalation trials with quantitative responses'.
Atkinson AC
Stat Med; 2009 Dec; 28(30):3739-41; discussion 3759-60. PubMed ID: 19967753
[No Abstract] [Full Text] [Related]
13. Commentary on 'Designs of dose-escalation trials with quantitative responses'.
Haines LM
Stat Med; 2009 Dec; 28(30):3742-4; discussion 3759-60. PubMed ID: 19967751
[No Abstract] [Full Text] [Related]
14. Determining causal exposure-response relationships with randomized concentration-controlled trials.
Wang J
J Biopharm Stat; 2014; 24(4):874-92. PubMed ID: 24697561
[TBL] [Abstract][Full Text] [Related]
15. Randomized exposure-controlled trials; impact of randomization and analysis strategies.
Karlsson KE; Grahnén A; Karlsson MO; Jonsson EN
Br J Clin Pharmacol; 2007 Sep; 64(3):266-77. PubMed ID: 17425629
[TBL] [Abstract][Full Text] [Related]
16. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
17. Commentary on 'Designs for dose-escalation trials with quantitative responses'.
O'Quigley J
Stat Med; 2009 Dec; 28(30):3745-50; discussion 3759-60. PubMed ID: 19967752
[TBL] [Abstract][Full Text] [Related]
18. [Study designs for the evaluation of drug effects].
Christensen S; Christiansen CF; Sørensen HT
Ugeskr Laeger; 2009 Mar; 171(10):799-802. PubMed ID: 19265605
[TBL] [Abstract][Full Text] [Related]
19. Optimising the design of phase II oncology trials: the importance of randomisation.
Ratain MJ; Sargent DJ
Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
[TBL] [Abstract][Full Text] [Related]
20. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes.
Resche-Rigon M; Zohar S; Chevret S
Clin Trials; 2008; 5(6):595-606. PubMed ID: 19029208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
